Financial Survey: Microbot Medical (NASDAQ:MBOT) vs. IDEXX Laboratories (NASDAQ:IDXX)

IDEXX Laboratories (NASDAQ:IDXX) and Microbot Medical (NASDAQ:MBOT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, institutional ownership, risk, earnings and dividends.

Valuation & Earnings

This table compares IDEXX Laboratories and Microbot Medical”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEXX Laboratories	$4.17 billion	14.43	$887.87 million	$12.61	59.72
Microbot Medical	N/A	N/A	-$11.44 million	($0.45)	-5.46

IDEXX Laboratories has higher revenue and earnings than Microbot Medical. Microbot Medical is trading at a lower price-to-earnings ratio than IDEXX Laboratories, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

87.8% of IDEXX Laboratories shares are held by institutional investors. Comparatively, 16.3% of Microbot Medical shares are held by institutional investors. 1.0% of IDEXX Laboratories shares are held by insiders. Comparatively, 4.7% of Microbot Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares IDEXX Laboratories and Microbot Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IDEXX Laboratories	24.41%	64.42%	29.89%
Microbot Medical	N/A	-76.27%	-67.54%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for IDEXX Laboratories and Microbot Medical, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEXX Laboratories	0	4	7	1	2.75
Microbot Medical	1	1	1	0	2.00

IDEXX Laboratories presently has a consensus target price of $730.50, suggesting a potential downside of 2.99%. Microbot Medical has a consensus target price of $12.00, suggesting a potential upside of 388.80%. Given Microbot Medical’s higher probable upside, analysts clearly believe Microbot Medical is more favorable than IDEXX Laboratories.

Volatility & Risk

IDEXX Laboratories has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, Microbot Medical has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.

Summary

IDEXX Laboratories beats Microbot Medical on 12 of the 14 factors compared between the two stocks.

About IDEXX Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. Additionally, the company offers human medical point-of-care products and laboratory diagnostics services. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

About Microbot Medical

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.